DM Intelligence is an artificial intelligence development company that built AI solutions for small molecule drugs with high specific and affinity. Our proprietary platform, Artificial Intelligence Drug Discovery Platform (AI-DDP), integrates artificial intelligence technologies into the medical field to provide better service to pharmaceutical companies, academic centers and biotech companies.
AI-DDP allow us to optimize leads with specific desired properties as well as design small molecules targeting specific site or receptor. Our platform has extensive capabilities of analyzing and predicting physicochemical properties, biological and toxicological activities of candidate drugs based on their structures. With all these techniques, we strive for break thoughts in the future of drug discovery and research.
Discovering a new drug is more challenge and difficult. Hit identification is the first step for a successful drug discovery project. Manual screening and high-throughput screening become cumbersome and expensive, which identify one or few compounds from hundreds, thousands or even millions of compounds with the ability to inhibit the activity of targets. We develop innovative solutions to this problem: using molecular geometry model and energy model based on structural information to predict molecule-protein interactions and identify right, validated and high-quality hits.
The quality of the candidate is the key determinant of a successful outcome of drug discovery programmes. Carrying out prediction studies prior to clinical development, such as analyzing and predicting physicochemical properties, biological and toxicological activities of candidate drugs may help in reducing workload, saving time, improving efficiency.